This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
A Daily Comprehensive Muscle Training Programme Increases Lean Mass and Spontaneous Activity in Children with Prader-Willi Syndrome after 6 Months
UNLABELLED The reduction of spontaneous physical activity ( PA ) and of muscle tissue are thought to be major causes of fat accretion and metabolic deterioration in Prader-Labhart-Willi syndrome ( PWS ) . We investigated whether a generalized physical training programme in a home setting improves these parameters . The prospect i ve study included 11 prepubertal children ( mean age 8.7 years , range 5.9 - 11.8 ) with documented PWS and under continuous growth hormone treatment for at least 2.8 years . Seven children were enrolled in a training programme for several muscle groups during 4 - 10 minutes daily .  Twelve matched children with PWS served as controls ( average age 8.8 years , 6.1 - 11.3 ) . Before and after training , at 6 months , PA was assessed by measuring  walking distance  by pedometer registration and by an activity score , and body composition by DEXA expressed as st and ard deviation scores ( SDS ) related to height . After training , lean mass ( LM ) increased from -1.83 to -1.48 SDS , p < 0.05 , whereas the controls showed no change . In the training group , walking distance and PA increased from 4.2 to 4.7 km/d and from 255 to 266 points , respectively , and these rises significantly exceeded those observed in controls . CONCLUSION Children with PWS can be motivated by their families to follow a short daily training , which has general effects on PA and does increase , but not normalize LM
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .